In a major consolidation move within the medical diagnostics industry, Abbott Laboratories (ABT) has announced a definitive agreement to acquire Exact Sciences (EXAS) for $21 billion. The deal sent Exact Sciences’ stock soaring, with shares up more than 17% on Thursday and rallying over 50% for the week.
Under the terms of the agreement, Exact Sciences stockholders will receive $105 per share in cash. This offer represents a nearly 22% premium to the stock’s closing price on Wednesday. The acquisition price underscores Abbott’s strong belief in Exact Sciences’ growth trajectory and its leading position in the high-value cancer diagnostics market.
The primary driver behind the acquisition is to combine forces to tackle the expansive and rapidly growing U.S. cancer screening and diagnostics industry, estimated to be worth $60 billion. Abbott is making a decisive push to become a leader in this field.
Exact Sciences is a cornerstone of this strategy. The company is renowned for its non-invasive Cologuard colorectal cancer screening test and its recently launched Cancerguard, the first commercially available multi-cancer early detection test.
“Abbott’s culture of innovation and global commercial reach will help accelerate our mission of eradicating cancer and expanding access to our tests worldwide, while delivering immediate and substantial value to our shareholders,” said Kevin Conroy, CEO of Exact Sciences. Robert Ford, CEO of Abbott, echoed this sentiment, stating, “Exact Sciences’ innovation, strong brand, and customer-focused execution are unrivaled in the cancer diagnostics space, and its presence and strengths are complementary to our own.”
Abbott’s move is a direct play to capture significant shares of three key market segments served by Exact’s products: the $45 billion colon and multi-cancer screening market, the $5 billion treatment guidance technology market, and the $15 billion molecular residual disease detection market.
The merger comes at a critical time. With approximately 2 million Americans and 20 million people globally diagnosed with cancer each year—a number projected to rise—the need for early detection is more pressing than ever. The combined entity aims to empower doctors with advanced diagnostic tools to detect cancer earlier, thereby making treatments more effective and ultimately saving more lives.
“Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives,” Conroy added.
The transaction, which is subject to regulatory approvals and the approval of Exact Sciences shareholders, is projected to close in the second quarter of 2026. For Exact Sciences shareholders, the deal offers a substantial premium to the company’s recent trading price, though it remains roughly 33% below the stock’s all-time high of nearly $160 per share, set in 2021.
With Exact’s current share price trading around $101, the deal leaves less than 4% upside until its expected close. This narrow gap presents a consideration for shareholders: if they have alternative investment ideas that could yield a better return over the approximately 18-month timeframe, they may consider exiting the position. Some investors might choose to sell early next year to potentially defer capital gains taxes until 2027.
